eHealth (EHTH) 10-Q 8 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 01, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-33071
Entity Registrant Name	EHEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-2357876
Entity Address, Address Line One	2625 AUGUSTINE DRIVE, SECOND FLOOR
Entity Address, City or Town	SANTA CLARA
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	650
Local Phone Number	584-2700
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	EHTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		26,388,112
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	[1]
Current assets:
Cash and cash equivalents	$ 157,530	$ 43,759
Short-term marketable securities	70,212	49,620
Accounts receivable	1,305	1,799
Contract assets – commissions receivable – current	194,197	219,153
Prepaid expenses and other current assets	36,653	16,661
Total current assets	459,897	330,992
Contract assets – commissions receivable – non-current	563,171	573,252
Property and equipment, net	13,795	14,609
Operating lease right-of-use assets	38,693	42,558
Restricted cash	3,354	3,354
Intangible assets, net	8,153	8,569
Goodwill	40,233	40,233
Other assets	32,307	26,455
Total assets	1,159,603	1,040,022
Current liabilities:
Accounts payable	10,084	36,921
Accrued compensation and benefits	20,424	20,542
Accrued marketing expenses	11,263	17,788
Lease liabilities – current	5,570	5,192
Deferred revenue	10,547	308
Other current liabilities	4,546	3,657
Total current liabilities	62,434	84,408
Deferred income taxes – non-current	52,185	72,317
Lease liabilities – non-current	37,138	41,369
Other non-current liabilities	4,747	4,370
Total liabilities	156,504	202,464
Commitments and contingencies
Convertible preferred stock	225,438	0
Stockholders’ equity:
Common stock	38	38
Additional paid-in capital	744,784	721,013
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings	232,519	316,155
Accumulated other comprehensive income	318	350
Total stockholders’ equity	777,661	837,558
Total liabilities, convertible preferred stock, and stockholders’ equity	$ 1,159,603	$ 1,040,022
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue:
Total revenue	$ 63,914	$ 94,284	$ 294,685	$ 289,458
Operating costs and expenses:
Cost of revenue	(25)	482	1,217	2,160
Marketing and advertising	43,317	33,405	138,772	104,042
Customer care and enrollment	48,956	43,342	121,480	101,025
Technology and content	20,369	17,673	63,996	46,786
General and administrative	16,640	19,942	57,812	60,308
Amortization of intangible assets	121	287	416	1,207
Restructuring and reorganization charges	573	0	3,004	0
Total operating costs and expenses	129,951	115,131	386,697	315,528
Loss from operations	(66,037)	(20,847)	(92,012)	(26,070)
Other income (expense), net	189	(101)	511	724
Loss before benefit from income taxes	(65,848)	(20,948)	(91,501)	(25,346)
Benefit from income taxes	(12,834)	(6,443)	(19,278)	(10,923)
Net loss	(53,014)	(14,505)	(72,223)	(14,423)
Paid-in-kind dividends for preferred stock	(4,561)	0	(7,643)	0
Change in preferred stock redemption value	(2,373)	0	(3,770)	0
Net loss attributable to common stockholders	$ (59,948)	$ (14,505)	$ (83,636)	$ (14,423)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)
Diluted (in dollars per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)
Weighted-average number of shares used in per share amounts:
Basic (in shares)	26,786	26,487	26,688	25,838
Diluted (in shares)	26,786	26,487	26,688	25,838
Comprehensive loss:
Net loss	$ (53,014)	$ (14,505)	$ (72,223)	$ (14,423)
Unrealized holding gain (loss) for available for sales debt securities, net of tax	3	(97)	(48)	71
Foreign currency translation adjustment	(26)	104	16	73
Comprehensive loss	(53,037)	(14,498)	(72,255)	(14,279)
Commission
Revenue:
Total revenue	59,191	73,544	276,066	253,986
Other
Revenue:
Total revenue	$ 4,723	$ 20,740	$ 18,619	$ 35,472

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total		Cumulative effect from the adoption of ASU 2016-13	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Retained EarningsCumulative effect from the adoption of ASU 2016-13	Accumulated Other Comprehensive Income
Beginning balance (in shares) at Dec. 31, 2019				34,752		11,616
Beginning Balance at Dec. 31, 2019	$ 527,164		$ (1,147)	$ 35	$ 455,159	$ (199,998)	$ 271,852	$ (1,147)	$ 116
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)				531
Issuance of common stock in connection with equity incentive plans	1,577			$ 1	1,576
Repurchase of shares to satisfy employee tax withholding obligations	(17,174)				(17,174)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)						194
Stock-based compensation	23,000				23,000
Other comprehensive income, net of tax	144								144
Net loss	(14,423)						(14,423)
Shares issued in equity offering (in shares)				2,070
Shares issued in equity offering	228,024			$ 2	228,022
Settlement of earnout liability (in shares)				295
Settlement of earnout liability	28,521				28,521
Ending balance (in shares) at Sep. 30, 2020				37,648		11,810
Ending Balance at Sep. 30, 2020	775,686			$ 38	719,104	$ (199,998)	256,282		260
Beginning balance (in shares) at Jun. 30, 2020				37,373		11,698
Beginning Balance at Jun. 30, 2020	792,055			$ 37	720,976	$ (199,998)	270,787		253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)				275
Issuance of common stock in connection with equity incentive plans	263			$ 1	262
Repurchase of shares to satisfy employee tax withholding obligations	(9,014)				(9,014)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)						112
Stock-based compensation	6,880				6,880
Other comprehensive income, net of tax	7								7
Net loss	(14,505)						(14,505)
Ending balance (in shares) at Sep. 30, 2020				37,648		11,810
Ending Balance at Sep. 30, 2020	775,686			$ 38	719,104	$ (199,998)	256,282		260
Beginning balance (in shares) at Dec. 31, 2020				37,755		11,831
Beginning Balance at Dec. 31, 2020	837,558	[1]		$ 38	721,013	$ (199,998)	316,155		350
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)				532
Issuance of common stock in connection with equity incentive plans	2,735				2,735
Repurchase of shares to satisfy employee tax withholding obligations	(7,968)				(7,968)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)						145
Paid-in-kind dividend and accretion related to convertible preferred stock	(11,413)						(11,413)
Issuance of common stock for employee stock purchase program (in shares)				38
Issuance of common stock for employee stock purchase program	2,248				2,248
Stock-based compensation	26,756				26,756
Other comprehensive income, net of tax	(32)								(32)
Net loss	(72,223)						(72,223)
Ending balance (in shares) at Sep. 30, 2021				38,325		11,976
Ending Balance at Sep. 30, 2021	777,661			$ 38	744,784	$ (199,998)	232,519		318
Beginning balance (in shares) at Jun. 30, 2021				38,094		11,925
Beginning Balance at Jun. 30, 2021	831,754			$ 38	738,906	$ (199,998)	292,467		341
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)				231
Issuance of common stock in connection with equity incentive plans	1,933				1,933
Repurchase of shares to satisfy employee tax withholding obligations	(2,061)				(2,061)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)						51
Paid-in-kind dividend and accretion related to convertible preferred stock	(6,934)						(6,934)
Stock-based compensation	6,006				6,006
Other comprehensive income, net of tax	(23)								(23)
Net loss	(53,014)						(53,014)
Ending balance (in shares) at Sep. 30, 2021				38,325		11,976
Ending Balance at Sep. 30, 2021	$ 777,661			$ 38	$ 744,784	$ (199,998)	$ 232,519		$ 318
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (72,223)	$ (14,423)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,700	2,604
Amortization of internally developed software	9,140	5,307
Amortization of intangible assets	416	1,207
Stock-based compensation expense	24,881	21,722
Deferred income taxes	(20,134)	(10,982)
Other non-cash items	908	421
Changes in operating assets and liabilities:
Accounts receivable	493	(1,522)
Contract assets – commissions receivable	35,244	(16,772)
Prepaid expenses and other assets	(20,790)	(9,398)
Accounts payable	(26,913)	(3,196)
Accrued compensation and benefits	(118)	(7,438)
Accrued marketing expenses	(6,525)	(5,449)
Deferred revenue	10,240	23,901
Accrued expenses and other liabilities	1,360	3,059
Net cash used in operating activities	(60,321)	(10,959)
Investing activities:
Capitalized internal-use software and website development costs	(12,589)	(12,082)
Purchases of property and equipment and other assets	(3,554)	(6,454)
Purchases of marketable securities	(88,967)	(180,505)
Proceeds from redemption and maturities of marketable securities	68,288	70,750
Net cash used in investing activities	(36,822)	(128,291)
Financing activities:
Proceeds from issuance of preferred stock, net of issuance costs	214,025	0
Proceeds from issuance of common stock, net of issuance costs	0	228,024
Net proceeds from exercise of common stock options and employee stock purchases	4,983	1,577
Repurchase of shares to satisfy employee tax withholding obligations	(7,968)	(17,174)
Acquisition-related contingent payments	0	(8,751)
Principal payments in connection with leases	(126)	(121)
Net cash provided by financing activities	210,914	203,555
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	62
Net increase in cash, cash equivalents and restricted cash	113,771	64,367
Cash, cash equivalents and restricted cash at beginning of period	47,113	26,820
Cash, cash equivalents and restricted cash at end of period	$ 160,884	$ 91,187

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 200 health insurance carriers across all fifty states and the District of Columbia. Basis of Presentation – The accompanying condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of comprehensive loss and stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The condensed consolidated balance sheet data as of December 31, 2020 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February 26, 2021 and amended on April 29, 2021. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 and include all adjustments necessary for the fair presentation of our financial position as of September 30, 2021 and December 31, 2020, and our results of operations for the periods presented. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2021 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share in our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. These items also reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share, on our Condensed Consolidated Statement of Comprehensive Loss for the nine months ended September 30, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting. Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2020. Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Our Medicare plan-related commission revenue is also elevated in the first quarter compared to the second and third quarters as a result of the reintroduction of the Medicare Advantage open enrollment period in the first quarter of 2019. Any changes to or adoption of open enrollment or special enrollment periods may change the seasonality of our business. The majority of our individual and family health insurance plans is sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. In the states where the Federally Facilitated marketplace operates as the state health insurance exchange, individuals and families generally are not able to purchase individual and family health insurance outside of the annual enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. Extended open enrollment or special enrollment periods may change the seasonality of our individual and family health insurance business. For example, the COVID-related special enrollment period which ended on August 15, 2021 has caused increased commission revenue from the sale of individual and family health insurance plans outside of the open enrollment period. In addition, we may experience changes in seasonality due to the extension of the 2022 open enrollment period to January 15, 2022 for most states. Recently Adopted Accounting Pronouncements Income Taxes (Topic 740) – In December 2019, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes , which aims to simplify the accounting for income taxes. We adopted this guidance in the first quarter of 2021, and it did not have a material impact on our condensed consolidated financial statements. Codification Improvements – In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements . ASU 2020-10 is intended to facilitate codification updates for technical corrections, such as conforming amendments, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements. It contains amendments that improve the consistency of the codification by including all disclosure guidance in the appropriate disclosure section and other updates that vary in nature. We adopted this guidance in the first quarter of 2021 with no material impact on our condensed consolidated financial statements and disclosures. Debt with Conversion and Other Options (Topic 470) and Contracts in Entity's Own Equity (Topic 815) – In June 2020, the FASB issued ASU No. 2020-06 to simplify the accounting for convertible instruments and improve the usefulness and relevance of information regarding convertible instruments. This ASU reduces the number of accounting models for converting debt instruments and convertible preferred stock. ASU No. 2020-06 is effective for us in 2022, with early adoption permitted. We early adopted this guidance in the first quarter of 2021, and it did not have a material impact on our condensed consolidated financial statements.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Medicare Medicare Advantage $ 36,557 $ 41,901 $ 209,224 $ 168,834 Medicare Supplement 3,214 7,321 15,357 32,384 Medicare Part D 1,338 329 (2,953) 7,148 Total Medicare 41,109 49,551 221,628 208,366 Individual and Family (1) Non-Qualified Health Plans 5,909 9,915 20,352 12,585 Qualified Health Plans 2,266 1,466 7,204 3,559 Total Individual and Family 8,175 11,381 27,556 16,144 Ancillary Short-term 1,370 2,438 4,639 6,724 Dental 3,938 4,452 9,326 5,791 Vision 642 1,798 1,781 2,228 Other 845 847 1,901 2,693 Total Ancillary 6,795 9,535 17,647 17,436 Small Business 2,190 1,723 7,703 6,975 Commission Bonus and Other 922 1,354 1,532 5,065 Total Commission Revenue 59,191 73,544 276,066 253,986 Other Revenue Sponsorship and Advertising Revenue 4,165 18,855 16,002 32,114 Other 558 1,885 2,617 3,358 Total Other Revenue 4,723 20,740 18,619 35,472 Total Revenue $ 63,914 $ 94,284 $ 294,685 $ 289,458 _____________ (1) We define our Individual and Family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are Individual and Family plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of those plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Medicare Commission Revenue from Members Approved During the Period (1) $ 42,698 $ 52,040 $ 235,974 $ 205,330 Net Commission Revenue from Members Approved in Prior Periods (2) (171) (698) (11,700) 8,966 Total Medicare Segment Commission Revenue $ 42,527 $ 51,342 $ 224,274 $ 214,296 Individual, Family and Small Business Commission Revenue from Members Approved During the Period (1) $ 4,892 $ 4,012 $ 16,495 $ 14,170 Commission Revenue from Renewals of Small Business Members During the Period (3) 1,744 1,122 6,154 5,005 Net Commission Revenue from Members Approved in Prior Periods (2) 10,028 17,068 29,143 20,515 Total IFP/SMB Segment Commission Revenue $ 16,664 $ 22,202 $ 51,792 $ 39,690 Total Commission Revenue from Members Approved During the Period (1) $ 47,590 $ 56,052 $ 252,469 $ 219,500 Commission Revenue from Renewals of Small Business Members During the Period (3) 1,744 1,122 6,154 5,005 Total Net Commission Revenue from Members Approved in Prior Periods (2)(4) 9,857 16,370 17,443 29,481 Total Commission Revenue $ 59,191 $ 73,544 $ 276,066 $ 253,986 _____________ (1) These amounts include commission bonus revenue. (2) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (3) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, beginning in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. (4) The impacts of total net commission revenue from members approved in prior periods were $0.37 and $0.62 per basic and diluted share for the three months ended September 30, 2021 and 2020, respectively. The impacts of total net commission revenue from members approved in prior periods were $0.65 and $1.14 per basic and diluted share, for the nine months ended September 30, 2021 and 2020, respectively. The total reductions to revenue from members approved in prior periods were $3.2 million and $3.7 million for the three months ended September 30, 2021 and 2020, respectively, and $22.6 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively. These reductions to revenue primarily related to the Medicare segment.

Supplemental Financial Statemen

Supplemental Financial Statement Information	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Statement Information	Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash $ 37,765 $ 39,552 Cash equivalents 119,765 4,207 Cash and cash equivalents 157,530 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 160,884 $ 47,113 As of September 30, 2021 and December 31, 2020, we had $3.4 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We do not require collateral or other security for our contract assets and accounts receivable. We believe the potential for collection issues with any of our customers was minimal as of September 30, 2021. We estimate an allowance for credit losses using relevant available information from internal and external sources, related to past events, current conditions, and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commission receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and included in general and administrative expense on our Condensed Consolidated Statement of Comprehensive Loss. There were no write-offs during any of the three or nine month periods ended September 30, 2021 and 2020. We considered the impact of recent events and global economic conditions when evaluating the appropriate adjustments to our allowance for credit losses as of September 30, 2021. We also considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic. The change in the allowance for credit losses for the nine months ended September 30, 2021 is summarized as follows (in thousands): Beginning balance $ 2,026 Change in allowance (207) Ending balance $ 1,819 Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Nine Months Ended September 30, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 235,974 16,495 252,469 Commission revenue from renewals of small business members during the period (1) — 6,154 6,154 Net commission revenue from members approved in prior periods (11,700) 29,143 17,443 Cash receipts (276,825) (34,485) (311,310) Net change in credit loss allowance 188 19 207 Ending balance $ 687,274 $ 70,094 $ 757,368 Nine Months Ended September 30, 2020 Medicare Segment IFP/SMB Segment Total Beginning balance $ 550,922 $ 38,300 $ 589,222 Commission revenue from members approved during the period 205,330 14,170 219,500 Commission revenue from renewals of small business members during the period (1) — 5,005 5,005 Net commission revenue from members approved in prior periods 8,966 20,515 29,481 Cash receipts (201,256) (35,957) (237,213) Net change in credit loss allowance (1,536) (114) (1,650) Ending balance $ 562,426 $ 41,919 $ 604,345 _____________ (1) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, starting in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable, and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $3.8 million as of September 30, 2021. See Note 4 – Fair Value Measurements for more information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below: September 30, 2021 December 31, 2020 Humana 27 % 21 % UnitedHealthCare (1) 24 % 21 % Aetna (1) 17 % 20 % Centene (1)(2) 8 % 11 % _____________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the contract assets and accounts receivable of WellCare are included in the percentage calculation for September 30, 2021 and December 31, 2020. Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): September 30, 2021 December 31, 2020 Prepaid maintenance contracts $ 8,448 $ 7,715 Prepaid licenses 3,302 — Prepaid expenses 23,828 6,628 Prepaid insurance 672 1,672 Others 403 646 Prepaid expenses and other current assets $ 36,653 $ 16,661

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): September 30, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 19,371 $ 19,371 $ — $ — $ 19,371 Commercial paper 100,394 — 100,394 — 100,394 Short-term marketable securities Agency bonds 1,276 — 1,276 — 1,276 Commercial paper 66,414 — 66,414 — 66,414 Corporate bond 2,522 — 2,522 — 2,522 Total assets measured at fair value $ 189,977 $ 19,371 $ 170,606 $ — $ 189,977 December 31, 2020 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 4,207 $ 4,207 $ — $ — $ 4,207 Short-term marketable securities Agency bonds 35,423 — 35,423 — 35,423 Commercial paper 14,197 — 14,197 — 14,197 Total assets measured at fair value $ 53,827 $ 4,207 $ 49,620 $ — $ 53,827 As of September 30, 2021, our cash equivalents consisted of money market funds and commercial paper with original maturity of 90 days or less were classified as Level 1 and 2, respectively. We endeavor to utilize the best available information in measuring fair value. We used observable prices in active markets in determining the classification of our money market funds as Level 1. Our Level 2 assets consisted of available for sale marketable securities, which included commercial paper, agency bonds, and a corporate bond with maturities of less than one year. We classify our marketable debt securities within Level 2 in the fair value hierarchy, because we use quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs to determine fair value. Our portfolio primarily consisted of financial instruments with a credit rating of AA or equivalent by S&P Rating and Moody's Investor Services. There were no transfers between the hierarchy levels during either the nine months ended September 30, 2021 or the year ended December 31, 2020. The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of September 30, 2021 Amortized Cost Fair Value Due in 1 year $ 189,980 $ 189,977 Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of September 30, 2021 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 19,371 $ — $ — $ 19,371 Commercial paper 100,398 — (4) 100,394 Short-term marketable securities Agency bonds 1,276 — — 1,276 Commercial paper 66,413 4 (3) 66,414 Corporate bond 2,522 — — 2,522 Total $ 189,980 $ 4 $ (7) $ 189,977

Equity

Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Equity	Equity 2021 Inducement Plan – On September 22, 2021, the Company adopted an inducement plan (the “2021 Inducement Plan”), pursuant to which the Company reserved 410,000 shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as an inducement material to the individual's entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules (“Nasdaq Rules”). The Inducement Plan was approved by the Company's board of directors (the “Board”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Rules, and the terms and conditions of the Inducement Plan and awards to be granted thereunder are substantially similar to the Company's stockholder-approved Amended and Restated 2014 Equity Incentive Plan. As of September 30, 2021, no shares were issued under the 2021 Inducement Plan. Subsequently, 390,584 shares were issued under the 2021 Inducement Plan in October 2021. Stock Repurchase Programs – We had no stock repurchase activity during the three and nine months ended September 30, 2021. In addition to 10.7 million shares repurchased under our previous repurchase programs, we have in treasury 1.3 million shares as of September 30, 2021 that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units. As of September 30, 2021 and December 31, 2020, we had a total of 12.0 million shares and 11.8 million shares, respectively, held in treasury. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Restricted stock units* $ 4,666 $ 6,078 $ 23,031 $ 20,855 Common stock options 82 254 402 867 Employee stock purchase plan 486 — 1,448 — Total stock-based compensation expense $ 5,234 $ 6,332 $ 24,881 $ 21,722 _________ * Amounts include market-based and performance-based restricted stock units. The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Marketing and advertising $ 2,297 $ 1,869 $ 6,922 $ 5,138 Customer care and enrollment 740 527 1,901 1,762 Technology and content 2,380 1,430 7,483 2,965 General and administrative* (183) 2,506 8,575 11,857 Total stock-based compensation expense $ 5,234 $ 6,332 $ 24,881 $ 21,722 Amount capitalized in internal-use software 772 548 1,875 1,278 Total stock-based compensation $ 6,006 $ 6,880 $ 26,756 $ 23,000 _________ * Stock-based compensation expense for both three and nine months ended September 30, 2021 was impacted by a $4.1 million credit related to forfeited equity awards due to our chief executive officer's separation.

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock On April 30, 2021 (the “Closing Date”), we issued and sold to Echelon Health SPV, LP (“H.I.G.”), an investment vehicle of H.I.G. Capital, in a private placement, 2,250,000 shares of our newly designated Series A convertible preferred stock (the “Series A preferred stock”), par value $0.001 per share, at an aggregate purchase price of $225.0 million. We received $214.0 million in net proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees totaling $11.0 million. The Series A preferred stock ranks senior to all other equity securities of the Company with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Dividends – Dividends initially accrue on the Series A preferred stock daily at 8% per annum on the stated value of $100 per share (“Stated Value”) and compound semiannually, payable in kind (“PIK”) until the second anniversary of the Closing Date on June 30 and December 31 of each year (each, a “Dividend Payment Date”), beginning on June 30, 2021, and thereafter 6% PIK and 2% payable in cash in arrears on June 30 and December 31 of each year, beginning on June 30, 2023. PIK dividends are cumulative and are added to the Accrued Value (as defined below). “Accrued Value” means, as of any date, with respect to any share of Series A preferred stock, the sum of the Stated Value per share plus, on each Dividend Payment Date, on a cumulative basis, all accrued PIK dividends on such share that have not previously compounded and been added to the Accrued Value. The Series A preferred stock participates, on an as-converted basis in all dividends paid to the holders of our common stock. Conversion Rights – The Series A preferred stock is convertible at any time into common stock at a conversion rate equal to (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the conversion price as of the applicable conversion date (the “Conversion Price”). As of the date of this report, the Conversion Price is equal to $79.5861 per share. This Conversion Price is subject to further adjustment and the number of shares of common stock issuable upon conversion of the Series A preferred stock is subject to certain limitations, each as set forth in the Certificate of Designations of Series A preferred stock, as filed with the Secretary of State of the State of Delaware on April 30, 2021 (the “Certificate of Designations”). Redemption Put Right – At any time on or after the sixth anniversary of the Closing Date, holders of the Series A preferred stock will have the right to cause the Company to redeem all or any portion of the Series A preferred stock in cash at an amount equal to the greater of (i) 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value and (ii) the amount per share that would be payable on an as-converted basis on such Series A preferred stock at the then-current Accrued Value, plus accrued PIK dividends that have not yet been added to the Accrued Value, and in either case of (i) or (ii) plus any unpaid cash dividends that would have otherwise been settled in cash in connection with such conversion (the greater of (i) and (ii), the “Redemption Price”). Redemption Call Right – At any time on or after the sixth anniversary of the Closing Date, the Company will have the right (but not the obligation) to redeem out of legally available funds and for cash consideration all (but not less than all) of the Series A preferred stock upon at least 30 days prior written notice at an amount equal to the Redemption Price. Board Nomination Rights – H.I.G. is entitled to nominate one individual for election to the the Board so long as it continues to own at least 30% of the common stock issuable or issued upon conversion of the Series A preferred stock originally issued to it in the private placement. H.I.G. also has the right to nominate an additional individual to the Board if the Company fails to maintain certain levels of commissions receivable and liquidity. Voting Rights – The Series A preferred stock will vote together with the common stock as a single class on all matters submitted to a vote of the holders of the common stock (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Each holder of Series A preferred stock shall be entitled to the number of votes, rounded down to the nearest whole number, equal to the product of (i) the aggregate Accrued Value of the issued and outstanding shares of Series A preferred stock divided by the Minimum Price (as defined below), multiplied by (ii) a fraction, the numerator of which is the number of shares of Series A preferred stock held by such holder and the denominator of which is the aggregate number of issued and outstanding shares of Series A preferred stock. “Minimum Price” means the lower of: (i) the Nasdaq Official Closing Price per share of common stock on the Closing Date; or (ii) the average Nasdaq Official Closing Price per share of common stock for the five trading days immediately prior to the Closing Date. Holders of Series A preferred stock will have one vote per share on any matter on which the holders of the Series A preferred stock are entitled to vote separately as a class (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Mandatory Conversion of the Series A Preferred Stock – At any time on or after the third anniversary of the Closing Date, if the volume-weighted average price per share of our common stock is greater than 167.5% of the then-current Conversion Price for 20 consecutive trading days in a 30-day trading day period, the Company will have the right to convert all, but not less than all, of the Series A preferred stock into common stock at a conversion rate with respect to each share of Series A preferred stock of (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the then applicable Conversion Price. Covenants and Liquidity Requirements – As long as H.I.G. continues to own at least 30% of the Series A preferred stock originally issued to it in the private placement, the consent of H.I.G. will be required for the Company to incur certain indebtedness and to take certain other corporate actions as set forth in the Company's investment agreement with H.I.G. entered into on February 17, 2021 (the “Investment Agreement”). In addition, the Company is required to maintain an asset coverage ratio (as defined in the Investment Agreement) of at least 2x, which increases to 2.5x thirty months after the date of the Investment Agreement. Additionally, the Investment Agreement requires the Company to maintain a minimum liquidity amount (as defined in the Investment Agreement) for certain periods that ranges from $65 million to $125 million. If the Company fails to maintain the minimum asset coverage ratio or minimum liquidity amount as of a certain date or for a certain time period required by the Investment Agreement and H.I.G continues to own at least 30% of the Series A preferred stock originally issued to it in the private placement, H.I.G will have the right to nominate an additional director to the Board, and the consent of H.I.G. will be required to approve the Company's annual budget, hire or terminate certain key executives, and incur certain indebtedness as outlined in the Investment Agreement. H.I.G. will no longer have these additional board nomination and consent rights if the Company is able to satisfy the minimum liquidity amount requirements in the Investment Agreement for any subsequent 12 consecutive months. Our Series A preferred stock is considered temporary equity in our condensed consolidated financial statements. We have determined there are no material embedded features that require recognition as a derivative asset or liability. We recognized the Series A preferred stock at its stated amount less issuance costs of $11.0 million, or $214.0 million. As of September 30, 2021, the estimated Series A preferred stock redemption value equals 135% of the Accrued Value per share as of the redemption date, plus any accrued and unpaid dividends, which is significantly in excess of the fair value of the common stock into which the Series A preferred stock is convertible as of September 30, 2021. We have elected to apply the accretion method to adjust the carrying value of the Series A preferred stock to its redemption value at the earliest date of redemption, April 30, 2027. Amounts recognized to accrete the Series A preferred stock to its estimated redemption value are treated as a deemed dividend and are recorded as a reduction to retained earnings. The estimated redemption value will vary in subsequent periods due to the redemption put right described above and we have elected to recognize such changes prospectively. No shares of Series A preferred stock have been converted and the Series A preferred stock was convertible into 2.9 million shares of common stock as of September 30, 2021. The following table summarizes the proceeds and changes to our Series A preferred stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs 10,975 Net proceeds $ 214,025 Balance as of Closing Date $ 214,025 Accrued paid-in-kind dividends 7,643 Change in preferred stock redemption value 3,770 Balance as of September 30, 2021 $ 225,438

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Our Series A preferred stock is considered a participating security which requires the use of two-class method for the computation of basic and diluted per share amounts. Under the two-class method, earnings available to common stockholders for the period are allocated between common stockholders and participating securities according to dividends accumulated and participation rights in undistributed earnings. Net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holder of the Series A preferred stock does not have a contractual obligation to share in losses. Basic net loss attributable to common stockholders per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss attributable to common stockholders per share reflects all potential dilutive common stock equivalent shares, including conversion of preferred stock, stock options, restricted stock units and shares to be issued under our employee stock purchase program (“ESPP”). The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ (59,948) $ (14,505) $ (83,636) $ (14,423) Denominator: Shares used in per share calculation – basic 26,786 26,487 26,688 25,838 Dilutive effect of common stock — — — — Shares used in diluted share calculation 26,786 26,487 26,688 25,838 Net loss attributable to common stockholders per share – basic and diluted $ (2.24) $ (0.55) $ (3.13) $ (0.56) For each of the three and nine months ended September 30, 2021 and 2020, we had securities outstanding that could potentially dilute per share amounts, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Convertible preferred stock 2,866 — 1,595 — Restricted stock units 1,134 599 1,055 748 Common stock options 278 414 330 453 ESPP 7 — 12 — Total 4,285 1,013 2,992 1,201

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance, and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of September 30, 2021 (in thousands): For the Years Ending December 31, Remainder of 2021 $ 2,845 2022 10,407 2023 8,067 2024 2,256 2025 — Thereafter — Total $ 23,575 Operating Leases Refer to Note 10 – Leases for commitments related to our operating leases. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. There was no material litigation-related accrual during the three and nine months ended September 30, 2021. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail. Legal Proceedings Securities Class Action – On April 8, 2020 and April 30, 2020, two purported class action lawsuits were filed against us, our then-chief executive officer, Scott N. Flanders, our then-chief financial officer, Derek N. Yung, and our then-chief operating officer, David K. Francis (collectively, the “Defendants”), in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al ., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al. , Case No. 4:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that we and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn and our profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. On June 24, 2020, the court consolidated the above-referenced matters under the caption In re eHealth Securities Litig. , Master File No. 4:20-cv-02395-JST (N.D. Cal.). The court also appointed a lead plaintiff and lead counsel for the consolidated matter. The lead plaintiff filed an amended complaint on August 25, 2020, which the Defendants moved to dismiss on October 23, 2020. The Defendants’ motion, which the plaintiff opposed, was granted in part and denied in part on August 12, 2021. The court dismissed the plaintiff's claims to the extent premised upon alleged misrepresentations or omissions relating to churn, but denied the Defendants motion with respect to alleged misstatements regarding purported operating costs. On October 1, 2021, the Company filed an answer denying in part and admitting in part the remaining allegations, and denying any wrongdoing. Derivative Actions – On July 7, 2020 and October 13, 2020, two derivative lawsuits were filed against our then-chief executive officer, Mr. Flanders, our then-chief financial officer, Mr. Yung, our then-chief operating officer, Mr. Francis, and the members of our Board at the time of filing of the complaints (collectively, the “Individual Defendants”), in the United States District Court for the Northern District of California and the Superior Court of California, County of Santa Clara. The cases are captioned Chernet v. Flanders et al ., Case No. 3:20-cv-04477-SK (N.D. Cal.), and Lincolnshire Police Pension Fund v. Flanders et al. , Case No. 20CV371555 (Cal. Super. Ct.), and also name the Company as a nominal defendant. A third derivative lawsuit was filed against the same defendants on October 5, 2021 in the United States District Court for the Northern District of California, captioned Badwal v. Flanders et al ., Case No. 4:21-cv-07795 (N.D. Cal.). The complaints allege, among other things, that beginning on March 19, 2018, the Individual Defendants made or caused the Company to make materially false and misleading statements and/or failed to disclose material information regarding our accounting and modeling assumptions, rate of member churn, profitability, and internal controls. The Chernet and Lincolnshire complaints purport to assert claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The Chernet lawsuit also alleges that the Individual Defendants violated Sections 14(a), 10(b), and 20(a) of the Securities Exchange Act of 1934, and asserts claims for abuse of control and gross mismanagement. The Badwal complaint purports to assert a claim for breach of fiduciary duty, an insider trading claim, and violations of Section 14(a), 10(b) and 20D of the Securities Exchange Act of 1934. The Chernet and Lincolnshire complaints seek damages, restitution, attorneys’ fees and costs, and certain measures with respect to our corporate governance and internal procedures, and (in the Lincolnshire lawsuit) equitable and/or injunctive relief. The Badwal complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys' fees and costs. On August 10, 2020, the parties filed a Stipulation and Proposed Order in the Chernet matter to stay the action until and through the resolution of the Defendants' anticipated motion to dismiss the consolidated securities class action, and filed a similar stipulation in the Lincolnshire matter on December 11, 2020. The Chernet stipulation was granted by the court on August 12, 2020 and the Lincolnshire stipulation on December 11, 2020. The agreed-upon stays terminated with the filing of an answer in the securities class action and the parties are engaged in discussions regarding further proceedings. The Gonzalez and Le ’ Vias Complaints

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating Segments We report segment information based on how our chief executive officer, who is our chief operating decision maker ("CODM"), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. The performance measures of our segments include total revenue and profit. Our business structure is comprised of two operating segments: Medicare and Individual, Family and Small Business. Please refer to Note 1 – Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2020 for our accounting policies relating to operating segments. The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenue: Medicare $ 46,381 $ 70,361 $ 240,633 $ 246,891 Individual, Family and Small Business 17,533 23,923 54,052 42,567 Total revenue $ 63,914 $ 94,284 $ 294,685 $ 289,458 Segment profit (loss): Medicare segment profit (loss) (1) $ (52,882) $ (14,139) $ (46,141) $ 23,993 Individual, Family and Small Business segment profit (1) 12,499 18,487 38,476 24,153 Total segment profit (loss) (40,383) 4,348 (7,665) 48,146 Corporate (14,827) (15,581) (43,206) (43,376) Stock-based compensation expense (5,234) (6,332) (24,881) (21,722) Depreciation and amortization (2) (4,899) (2,995) (12,840) (7,911) Amortization of intangible assets (121) (287) (416) (1,207) Restructuring and reorganization charges (573) — (3,004) — Other income (expense), net 189 (101) 511 724 Loss before benefit from income taxes $ (65,848) $ (20,948) $ (91,501) $ (25,346) _____________ (1) During the first quarter of 2021, we revised the calculation of segment profit by excluding amortization of capitalized software development costs to enhance comparability of our financial metrics with peer companies. The amortization of capitalized software development costs were $3.4 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and $9.1 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively. (2) Depreciation and amortization has been adjusted to include amortization of software development costs. There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information , our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. Geographic Information Our long-lived assets primarily consist of property and equipment and internally-developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): September 30, 2021 December 31, 2020 United States $ 45,465 $ 40,500 China 637 565 Total $ 46,102 $ 41,065 Significant Customers Substantially all revenue for the three and nine months ended September 30, 2021 and 2020 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 UnitedHealthCare (1) 21 % 17 % 21 % 21 % Aetna (1) 15 % 12 % 20 % 14 % Humana 20 % 26 % 18 % 21 % Centene (2) 11 % 8 % 12 % 10 % __________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the revenue of WellCare is included in the percentage calculation for the three and nine months ended September 30, 2021 and 2020.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	Leases Our leases have remaining lease terms of 2 to 8 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Total operating lease expenses were $1.9 million and $2.1 million for the three months ended September 30, 2021 and 2020, and $5.7 million and $6.4 million for the nine months ended September 30, 2021 and 2020, respectively and sublease income was immaterial for both periods. Supplemental information related to leases are as follows (dollars in thousands): September 30, 2021 December 31, 2020 Weighted-average remaining lease term of operating leases 6.6 years 7.2 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % Nine Months Ended September 30, 2021 2020 Operating lease expense $ 5,738 $ 6,411 Cash outflows related to operating leases 5,722 5,173 As of September 30, 2021, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2021 $ 1,926 2022 7,701 2023 8,033 2024 7,832 2025 8,009 Thereafter 19,407 Total lease payments (1) 52,908 Less imputed interest (10,200) Total $ 42,708 ____________ (1) Noncancellable sublease income for the remainder of 2021 and years ending December 31, 2022 and 2023 of $0.3 million, $0.4 million, and $0.4 million, respectively, is not included in the table above.

Restructuring and Reorganizatio

Restructuring and Reorganization	9 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Reorganization	Restructuring and Reorganization Our restructuring and reorganization costs and liabilities consist primarily of severance, transition and other related costs. The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Nine Months Ended September 30, 2021 Beginning balance $ — Restructuring and reorganization charges 3,004 Payments (2,466) Ending balance $ 538 In February 2021, we eliminated approximately 89 full-time positions, primarily in the United States, representing approximately 5% of our workforce, primarily within our customer care and enrollment group, and to a lesser extent, in our marketing and advertising, technology and content, and general and administrative groups. Total pre-tax restructuring charges were $2.4 million for the nine months ended September 30, 2021, which primarily related to employee termination benefits. Substantially all of the restructuring charges resulted in cash expenditures. The restructuring activities were completed by March 31, 2021. In September 2021, we announced the transition of our chief executive officer. Mr. Scott Flanders resigned as a member of our Board and chief executive officer, effective October 31, 2021. We recognized $0.5 million in severance costs related to his separation in September 2021 and we expect to recognize an additional $1.9 million in the fourth quarter of 2021. Stock-based compensation expense for both three and nine months ended September 30, 2021 was impacted by a $4.1 million credit related to forfeited equity awards due to Mr. Flanders' separation, which was included in general and administrative expenses on our Condensed Consolidated Statement of Comprehensive Loss.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	Debt On September 17, 2018, we entered into a Credit Agreement with Royal Bank of Canada (“RBC”), as administrative agent and collateral agent (the “Credit Agreement”). The Credit Agreement provides for a $40.0 million secured asset-backed revolving credit facility with a $5.0 million letter of credit sub-facility. On December 20, 2019, we amended our revolving credit facility agreement with RBC (the “Amendment”) and increased the borrowing amount from $40.0 million to $75.0 million. The maturity date has been extended to December 20, 2022. The borrowing base under the Credit Agreement is comprised of an amount equal to (a) the lesser of (i) eighty percent (80%) of Eligible Commissions Receivables (as defined in the Credit Agreement) we actually collected during the immediately preceding period of three months or (ii) eighty percent (80%) of our Eligible Commission Receivables for the immediately succeeding period of three months, plus (b) fifty percent (50%) of our Eligible Commission Receivables for the immediately succeeding period of six months (excluding the immediately succeeding period of three months), in each case subject to reserves established by RBC (the “Borrowing Base”). The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes. The borrowers have the right to prepay the loans under the Credit Agreement in whole or in part at any time without penalty. Subject to availability under the Borrowing Base, amounts repaid may be reborrowed. Amounts not borrowed under the Credit Agreement will be subject to a commitment fee of 0.5% per annum on the daily unused portion of the credit facility, to be paid in arrears on the first business day of each calendar quarter. At the closing of the Credit Agreement, we paid a one-time facility fee of 1.75% of the total commitments of $40.0 million. We also paid a one-time closing fee of 0.5% of the new commitment of $75.0 million in connection with the Amendment. The Company is also obligated to pay other customary administration fees for a credit facility of this size and type. The availability under the credit facility was up to the lesser of $40.0 million or the Borrowing Base in the original credit agreement. The Amendment increased the availability up to the lesser of $75.0 million or the Borrowing Base, which may be reduced from time to time pursuant to the Credit Agreement. Financial covenants in the original Credit Agreement required that we maintain Excess Availability (as defined in the Credit Agreement) at or above $6.0 million at any time. The Amendment also changed the financial covenants to require us to maintain at least $6.0 million of Excess Availability at all times or, if greater, up to $11.3 million depending on our Borrowing Base as determined by eligible past and future commissions receivable. In addition, the Amendment also included changes in the payment conditions to, among other things, require us to have at least $10.0 million of liquidity or, if greater, up to $18.8 million depending on the Borrowing Base as determined by eligible past and future commissions receivable, in order for us to make certain permitted acquisitions, investments, distributions and payments of indebtedness. The Amendment also stated the seasonal amount thresholds used in connection with the cash dominion and field examination covenants in the Credit Agreement. We incurred $1.2 million of issuance costs in connection with the Credit Agreement, which were capitalized as part of other assets on our Consolidated Balance Sheet in the period we entered into the Credit Agreement. The Amendment did not change the interest rate. In connection with the Amendment, we incurred closing costs totaling $0.5 million, which were capitalized and recorded as other assets on our Consolidated Balance Sheet as of December 31, 2019. The remaining balance of unamortized issuance costs was $0.5 million and $0.7 million as of September 30, 2021 and December 31, 2020, respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Loss before benefit from income taxes $ (65,848) $ (20,948) $ (91,501) $ (25,346) Benefit from income taxes (12,834) (6,443) (19,278) (10,923) Effective tax rate 19.5 % 30.8 % 21.1 % 43.1 % For the three and nine months ended September 30, 2021, we recognized a benefit from income taxes of $12.8 million and $19.3 million, representing an effective tax rate of 19.5% and 21.1%, respectively. These effective tax rates are higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses and state taxes, partially offset by research and development credits. For the three and nine months ended September 30, 2020, we recognized benefits from income taxes of $6.4 million and $10.9 million, representing an effective tax rate of 30.8% and 43.1%, respectively, which were higher than the statutory federal tax rate due primarily to stock-based compensation adjustments, non-deductible lobbying expenses and state taxes, partially offset by research and development credits. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of September 30, 2021, as we believe it is more likely than not that the net deferred tax assets will be realized, with the exception of certain net operating losses and credits that are expected to expire unutilized which have a valuation allowance.

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business – eHealth, Inc. (the “Company,” “eHealth,” “we” or “us”) is a leading health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to connect every person with the highest quality, most affordable health insurance and Medicare plans for their life circumstances. Our platform integrates proprietary and third-party developed educational content regarding health insurance plans with decision support tools to aid consumers in what has traditionally been a confusing and opaque health insurance purchasing process, and to help them obtain the health insurance products that meet their individual health and economic needs. Our omnichannel consumer engagement platform enables consumers to use our services online, through interactive chat, or by telephone with a licensed insurance agent. We have created a marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual and family, small business and other ancillary health insurance products from over 200 health insurance carriers across all fifty states and the District of Columbia.
Basis of Presentation	Basis of Presentation – The accompanying condensed consolidated balance sheet as of September 30, 2021, the condensed consolidated statements of comprehensive loss and stockholders’ equity for the three and nine months ended September 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are unaudited. The condensed consolidated balance sheet data as of December 31, 2020 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission on February 26, 2021 and amended on April 29, 2021. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. Certain prior period amounts have been reclassified to conform with our current period presentation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 and include all adjustments necessary for the fair presentation of our financial position as of September 30, 2021 and December 31, 2020, and our results of operations for the periods presented. The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2021 and therefore should not be relied upon as an indicator of future results. Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2020, we identified certain errors, including a $3.0 million under-recognition of stock-based compensation expense and a $1.5 million over-recognition of licensing costs for the year ended December 31, 2020. We adjusted for these items in the first quarter of 2021 and the adjustments reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share in our Condensed Consolidated Statement of Comprehensive Loss for the three months ended March 31, 2021. These items also reduced our net loss by approximately $1.5 million, or $0.06 per basic and diluted share, on our Condensed Consolidated Statement of Comprehensive Loss for the nine months ended September 30, 2021. We evaluated the effects of these out-of-period adjustments, both qualitatively and quantitatively, and concluded that the errors and the correction thereof were immaterial both individually and in the aggregate to the current reporting period and the periods in which they originated, including quarterly reporting.
Significant Accounting Policies, Estimates and Judgments	Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the useful lives of intangible assets, fair value of investments, recoverability of intangible assets, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.
Seasonality	Seasonality – Open enrollment periods drive the seasonality of our business. A greater number of our Medicare-related health insurance plans are sold in our fourth quarter during the Medicare annual enrollment period when Medicare-eligible individuals are permitted to change their Medicare Advantage and Medicare Part D prescription drug coverage for the following year. As a result, our Medicare plan-related commission revenue is highest in our fourth quarter. Our Medicare plan-related commission revenue is also elevated in the first quarter compared to the second and third quarters as a result of the reintroduction of the Medicare Advantage open enrollment period in the first quarter of 2019. Any changes to or adoption of open enrollment or special enrollment periods may change the seasonality of our business. The majority of our individual and family health insurance plans is sold in the fourth quarter during the annual open enrollment period as defined under the federal Patient Protection and Affordable Care Act and related amendments in the Health Care and Education Reconciliation Act. In the states where the Federally Facilitated marketplace operates as the state health insurance exchange, individuals and families generally are not able to purchase individual and family health insurance outside of the annual enrollment period, unless they qualify for a special enrollment period as a result of certain qualifying events, such as losing employer-sponsored health insurance or moving to another state. Extended open enrollment or special enrollment periods may change the seasonality of our individual and family health insurance business. For example, the COVID-related special enrollment period which ended on August 15, 2021 has caused increased commission revenue from the sale of individual and family health insurance plans outside of the open enrollment period. In addition, we may experience changes in seasonality due to the extension of the 2022 open enrollment period to January 15, 2022 for most states.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Income Taxes (Topic 740) – In December 2019, the Financial Accounting Standard Board (“FASB”) issued ASU No. 2019-12, Income Tax, Simplifying the Accounting for Income Taxes , which aims to simplify the accounting for income taxes. We adopted this guidance in the first quarter of 2021, and it did not have a material impact on our condensed consolidated financial statements. Codification Improvements – In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements . ASU 2020-10 is intended to facilitate codification updates for technical corrections, such as conforming amendments, clarifications to guidance, simplifications to wording or structure of guidance, and other minor improvements. It contains amendments that improve the consistency of the codification by including all disclosure guidance in the appropriate disclosure section and other updates that vary in nature. We adopted this guidance in the first quarter of 2021 with no material impact on our condensed consolidated financial statements and disclosures. Debt with Conversion and Other Options (Topic 470) and Contracts in Entity's Own Equity (Topic 815) – In June 2020, the FASB issued ASU No. 2020-06 to simplify the accounting for convertible instruments and improve the usefulness and relevance of information regarding convertible instruments. This ASU reduces the number of accounting models for converting debt instruments and convertible preferred stock. ASU No. 2020-06 is effective for us in 2022, with early adoption permitted. We early adopted this guidance in the first quarter of 2021, and it did not have a material impact on our condensed consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Segment	Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Medicare Medicare Advantage $ 36,557 $ 41,901 $ 209,224 $ 168,834 Medicare Supplement 3,214 7,321 15,357 32,384 Medicare Part D 1,338 329 (2,953) 7,148 Total Medicare 41,109 49,551 221,628 208,366 Individual and Family (1) Non-Qualified Health Plans 5,909 9,915 20,352 12,585 Qualified Health Plans 2,266 1,466 7,204 3,559 Total Individual and Family 8,175 11,381 27,556 16,144 Ancillary Short-term 1,370 2,438 4,639 6,724 Dental 3,938 4,452 9,326 5,791 Vision 642 1,798 1,781 2,228 Other 845 847 1,901 2,693 Total Ancillary 6,795 9,535 17,647 17,436 Small Business 2,190 1,723 7,703 6,975 Commission Bonus and Other 922 1,354 1,532 5,065 Total Commission Revenue 59,191 73,544 276,066 253,986 Other Revenue Sponsorship and Advertising Revenue 4,165 18,855 16,002 32,114 Other 558 1,885 2,617 3,358 Total Other Revenue 4,723 20,740 18,619 35,472 Total Revenue $ 63,914 $ 94,284 $ 294,685 $ 289,458 _____________ (1) We define our Individual and Family plan offerings as major medical individual and family health insurance plans, which does not include Medicare-related, small business or ancillary plans. Individual and family health insurance plans include both qualified and non-qualified plans. Qualified health plans are individual and family health insurance plans that meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans are Individual and Family plans that meet the requirements of the Affordable Care Act and are not offered through the exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of those plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Medicare Commission Revenue from Members Approved During the Period (1) $ 42,698 $ 52,040 $ 235,974 $ 205,330 Net Commission Revenue from Members Approved in Prior Periods (2) (171) (698) (11,700) 8,966 Total Medicare Segment Commission Revenue $ 42,527 $ 51,342 $ 224,274 $ 214,296 Individual, Family and Small Business Commission Revenue from Members Approved During the Period (1) $ 4,892 $ 4,012 $ 16,495 $ 14,170 Commission Revenue from Renewals of Small Business Members During the Period (3) 1,744 1,122 6,154 5,005 Net Commission Revenue from Members Approved in Prior Periods (2) 10,028 17,068 29,143 20,515 Total IFP/SMB Segment Commission Revenue $ 16,664 $ 22,202 $ 51,792 $ 39,690 Total Commission Revenue from Members Approved During the Period (1) $ 47,590 $ 56,052 $ 252,469 $ 219,500 Commission Revenue from Renewals of Small Business Members During the Period (3) 1,744 1,122 6,154 5,005 Total Net Commission Revenue from Members Approved in Prior Periods (2)(4) 9,857 16,370 17,443 29,481 Total Commission Revenue $ 59,191 $ 73,544 $ 276,066 $ 253,986 _____________ (1) These amounts include commission bonus revenue. (2) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (3) Commission revenue from renewals of small business members during the period was previously included in net commission revenue from members approved in prior periods. However, beginning in the first quarter of 2021, we enhanced our reporting by separately disclosing commission revenue from renewals of small business members during the period in a separate line item. (4) The impacts of total net commission revenue from members approved in prior periods were $0.37 and $0.62 per basic and diluted share for the three months ended September 30, 2021 and 2020, respectively. The impacts of total net commission revenue from members approved in prior periods were $0.65 and $1.14 per basic and diluted share, for the nine months ended September 30, 2021 and 2020, respectively. The total reductions to revenue from members approved in prior periods were $3.2 million and $3.7 million for the three months ended September 30, 2021 and 2020, respectively, and $22.6 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively. These reductions to revenue primarily related to the Medicare segment.

Supplemental Financial Statem_2

Supplemental Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule Of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash $ 37,765 $ 39,552 Cash equivalents 119,765 4,207 Cash and cash equivalents 157,530 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 160,884 $ 47,113
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalent and restricted cash balances are summarized as follows (in thousands): September 30, 2021 December 31, 2020 Cash $ 37,765 $ 39,552 Cash equivalents 119,765 4,207 Cash and cash equivalents 157,530 43,759 Restricted cash 3,354 3,354 Total cash, cash equivalents and restricted cash $ 160,884 $ 47,113
Schedule of Change in Allowance for Credit Loss	The change in the allowance for credit losses for the nine months ended September 30, 2021 is summarized as follows (in thousands): Beginning balance $ 2,026 Change in allowance (207) Ending balance $ 1,819
Schedule of Contract Assets - Commissions Receivable	Our contract assets – commission receivable activities, net of credit loss allowances are summarized as follows (in thousands): Nine Months Ended September 30, 2021 Medicare Segment IFP/SMB Segment Total Beginning balance $ 739,637 $ 52,768 $ 792,405 Commission revenue from members approved during the period 235,974 16,495 252,469 Commission revenue from renewals of small business members during the period (1) — 6,154 6,154 Net commission revenue from members approved in prior periods (11,700) 29,143 17,443 Cash receipts (276,825) (34,485) (311,310) Net change in credit loss allowance 188 19 207 Ending balance $ 687,274 $ 70,094 $ 757,368 Nine Months Ended September 30, 2020 Medicare Segment IFP/SMB Segment Total Beginning balance $ 550,922 $ 38,300 $ 589,222 Commission revenue from members approved during the period 205,330 14,170 219,500 Commission revenue from renewals of small business members during the period (1) — 5,005 5,005 Net commission revenue from members approved in prior periods 8,966 20,515 29,481 Cash receipts (201,256) (35,957) (237,213) Net change in credit loss allowance (1,536) (114) (1,650) Ending balance $ 562,426 $ 41,919 $ 604,345 _____________
Schedule of Credit Risk	Carriers that represented 10% or more of our total contract assets and accounts receivable balance are summarized as of the dates presented below: September 30, 2021 December 31, 2020 Humana 27 % 21 % UnitedHealthCare (1) 24 % 21 % Aetna (1) 17 % 20 % Centene (1)(2) 8 % 11 % _____________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the contract assets and accounts receivable of WellCare are included in the percentage calculation for September 30, 2021 and December 31, 2020.
Schedule Of Prepaid Expenses And Other Current Assets	Our prepaid expenses and other current assets are summarized as of the periods presented as follows (in thousands): September 30, 2021 December 31, 2020 Prepaid maintenance contracts $ 8,448 $ 7,715 Prepaid licenses 3,302 — Prepaid expenses 23,828 6,628 Prepaid insurance 672 1,672 Others 403 646 Prepaid expenses and other current assets $ 36,653 $ 16,661

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability.
Summary of Financial Assets Measured at Fair Value on a Recurring Basis	Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy as of the dates presented below (in thousands): September 30, 2021 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 19,371 $ 19,371 $ — $ — $ 19,371 Commercial paper 100,394 — 100,394 — 100,394 Short-term marketable securities Agency bonds 1,276 — 1,276 — 1,276 Commercial paper 66,414 — 66,414 — 66,414 Corporate bond 2,522 — 2,522 — 2,522 Total assets measured at fair value $ 189,977 $ 19,371 $ 170,606 $ — $ 189,977 December 31, 2020 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 4,207 $ 4,207 $ — $ — $ 4,207 Short-term marketable securities Agency bonds 35,423 — 35,423 — 35,423 Commercial paper 14,197 — 14,197 — 14,197 Total assets measured at fair value $ 53,827 $ 4,207 $ 49,620 $ — $ 53,827
Summary of Contractual Maturities	The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of September 30, 2021 Amortized Cost Fair Value Due in 1 year $ 189,980 $ 189,977
Summary of Unrealized Gains and Losses	Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income and summarized as follows as of September 30, 2021 (in thousands): Amortized Cost Unrealized Gain Unrealized Loss Fair Value Cash equivalents Money market funds $ 19,371 $ — $ — $ 19,371 Commercial paper 100,398 — (4) 100,394 Short-term marketable securities Agency bonds 1,276 — — 1,276 Commercial paper 66,413 4 (3) 66,414 Corporate bond 2,522 — — 2,522 Total $ 189,980 $ 4 $ (7) $ 189,977

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule Of Stock-Based Compensation Expense By Award Type	Our stock-based compensation expense is summarized as follows by award types (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Restricted stock units* $ 4,666 $ 6,078 $ 23,031 $ 20,855 Common stock options 82 254 402 867 Employee stock purchase plan 486 — 1,448 — Total stock-based compensation expense $ 5,234 $ 6,332 $ 24,881 $ 21,722 _________ * Amounts include market-based and performance-based restricted stock units.
Schedule Of Stock-Based Compensation Expense By Operating Function	The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Marketing and advertising $ 2,297 $ 1,869 $ 6,922 $ 5,138 Customer care and enrollment 740 527 1,901 1,762 Technology and content 2,380 1,430 7,483 2,965 General and administrative* (183) 2,506 8,575 11,857 Total stock-based compensation expense $ 5,234 $ 6,332 $ 24,881 $ 21,722 Amount capitalized in internal-use software 772 548 1,875 1,278 Total stock-based compensation $ 6,006 $ 6,880 $ 26,756 $ 23,000 _________ * Stock-based compensation expense for both three and nine months ended September 30, 2021 was impacted by a $4.1 million credit related to forfeited equity awards due to our chief executive officer's separation.

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Summary of Convertible Preferred Stock	The following table summarizes the proceeds and changes to our Series A preferred stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs 10,975 Net proceeds $ 214,025 Balance as of Closing Date $ 214,025 Accrued paid-in-kind dividends 7,643 Change in preferred stock redemption value 3,770 Balance as of September 30, 2021 $ 225,438

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator: Net loss attributable to common stockholders $ (59,948) $ (14,505) $ (83,636) $ (14,423) Denominator: Shares used in per share calculation – basic 26,786 26,487 26,688 25,838 Dilutive effect of common stock — — — — Shares used in diluted share calculation 26,786 26,487 26,688 25,838 Net loss attributable to common stockholders per share – basic and diluted $ (2.24) $ (0.55) $ (3.13) $ (0.56)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net income (loss) per share consisted of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Convertible preferred stock 2,866 — 1,595 — Restricted stock units 1,134 599 1,055 748 Common stock options 278 414 330 453 ESPP 7 — 12 — Total 4,285 1,013 2,992 1,201

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Contractual Obligations	Our future minimum payments under non-cancellable contractual service and licensing obligations as of September 30, 2021 (in thousands): For the Years Ending December 31, Remainder of 2021 $ 2,845 2022 10,407 2023 8,067 2024 2,256 2025 — Thereafter — Total $ 23,575

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenue: Medicare $ 46,381 $ 70,361 $ 240,633 $ 246,891 Individual, Family and Small Business 17,533 23,923 54,052 42,567 Total revenue $ 63,914 $ 94,284 $ 294,685 $ 289,458 Segment profit (loss): Medicare segment profit (loss) (1) $ (52,882) $ (14,139) $ (46,141) $ 23,993 Individual, Family and Small Business segment profit (1) 12,499 18,487 38,476 24,153 Total segment profit (loss) (40,383) 4,348 (7,665) 48,146 Corporate (14,827) (15,581) (43,206) (43,376) Stock-based compensation expense (5,234) (6,332) (24,881) (21,722) Depreciation and amortization (2) (4,899) (2,995) (12,840) (7,911) Amortization of intangible assets (121) (287) (416) (1,207) Restructuring and reorganization charges (573) — (3,004) — Other income (expense), net 189 (101) 511 724 Loss before benefit from income taxes $ (65,848) $ (20,948) $ (91,501) $ (25,346) _____________ (1) During the first quarter of 2021, we revised the calculation of segment profit by excluding amortization of capitalized software development costs to enhance comparability of our financial metrics with peer companies. The amortization of capitalized software development costs were $3.4 million and $2.1 million for the three months ended September 30, 2021 and 2020, respectively, and $9.1 million and $5.3 million for the nine months ended September 30, 2021 and 2020, respectively.
Schedule Of Long Lived Assets By Geographical Areas	Long-lived assets by geographical area are summarized as follows (in thousands): September 30, 2021 December 31, 2020 United States $ 45,465 $ 40,500 China 637 565 Total $ 46,102 $ 41,065
Schedule Of Revenue By Major Customers	Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 UnitedHealthCare (1) 21 % 17 % 21 % 21 % Aetna (1) 15 % 12 % 20 % 14 % Humana 20 % 26 % 18 % 21 % Centene (2) 11 % 8 % 12 % 10 % __________ (1) Percentages include the carriers' subsidiaries. (2) Centene Corporation acquired WellCare Health Plans, Inc. in 2020, and the revenue of WellCare is included in the percentage calculation for the three and nine months ended September 30, 2021 and 2020.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Schedule of Supplemental Information	Supplemental information related to leases are as follows (dollars in thousands): September 30, 2021 December 31, 2020 Weighted-average remaining lease term of operating leases 6.6 years 7.2 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.4 % 5.4 % Nine Months Ended September 30, 2021 2020 Operating lease expense $ 5,738 $ 6,411 Cash outflows related to operating leases 5,722 5,173
Schedule of Operating Lease Maturities	As of September 30, 2021, maturities of operating lease liabilities are as follows (in thousands): Year ending December 31, Remainder of 2021 $ 1,926 2022 7,701 2023 8,033 2024 7,832 2025 8,009 Thereafter 19,407 Total lease payments (1) 52,908 Less imputed interest (10,200) Total $ 42,708 ____________ (1) Noncancellable sublease income for the remainder of 2021 and years ending December 31, 2022 and 2023 of $0.3 million, $0.4 million, and $0.4 million, respectively, is not included in the table above.

Restructuring and Reorganizat_2

Restructuring and Reorganization (Tables)	9 Months Ended
	Sep. 30, 2021
Restructuring and Related Activities [Abstract]
Summary of Restructuring and Other Related Liabilities	The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Nine Months Ended September 30, 2021 Beginning balance $ — Restructuring and reorganization charges 3,004 Payments (2,466) Ending balance $ 538

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule Of Components Of Income Tax Expense	The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Loss before benefit from income taxes $ (65,848) $ (20,948) $ (91,501) $ (25,346) Benefit from income taxes (12,834) (6,443) (19,278) (10,923) Effective tax rate 19.5 % 30.8 % 21.1 % 43.1 %

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies - Narrative (Details) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)insurance_carrierstate$ / shares	Mar. 31, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)$ / shares	Sep. 30, 2021USD ($)insurance_carrierstate$ / shares	Sep. 30, 2020USD ($)$ / shares	Dec. 31, 2020USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Number of health insurance carriers (more than) | insurance_carrier	200			200
Number of states in which the Company is licensed to market and sell health insurance | state	50			50
Total stock-based compensation expense	$ 5,234		$ 6,332	$ 24,881	$ 21,722
Cost of revenue	(25)		482	1,217	2,160
Change in net income (loss)	$ 53,014		$ 14,505	$ 72,223	$ 14,423
Basic (in dollars per share) | $ / shares	$ (2.24)		$ (0.55)	$ (3.13)	$ (0.56)
Diluted (in dollars per share) | $ / shares	$ (2.24)		$ (0.55)	$ (3.13)	$ (0.56)
Under-Recognition Of Stock-Based Compensation Expense
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Total stock-based compensation expense						$ 3,000
Out-Of-Period Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Change in net income (loss)		$ 1,500		$ 1,500
Basic (in dollars per share) | $ / shares		$ 0.06		$ 0.06
Diluted (in dollars per share) | $ / shares		$ 0.06		$ 0.06
License | Over-Recognition Of Licensing Costs
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of revenue						$ 1,500

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 63,914	$ 94,284	$ 294,685	$ 289,458
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	41,109	49,551	221,628	208,366
Medicare | Medicare Advantage
Disaggregation of Revenue [Line Items]
Total revenue	36,557	41,901	209,224	168,834
Medicare | Medicare Supplement
Disaggregation of Revenue [Line Items]
Total revenue	3,214	7,321	15,357	32,384
Medicare | Medicare Part D
Disaggregation of Revenue [Line Items]
Total revenue	1,338	329	(2,953)	7,148
Individual and Family
Disaggregation of Revenue [Line Items]
Total revenue	8,175	11,381	27,556	16,144
Individual and Family | Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	5,909	9,915	20,352	12,585
Individual and Family | Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	2,266	1,466	7,204	3,559
Ancillary
Disaggregation of Revenue [Line Items]
Total revenue	6,795	9,535	17,647	17,436
Ancillary | Short-term
Disaggregation of Revenue [Line Items]
Total revenue	1,370	2,438	4,639	6,724
Ancillary | Dental
Disaggregation of Revenue [Line Items]
Total revenue	3,938	4,452	9,326	5,791
Ancillary | Vision
Disaggregation of Revenue [Line Items]
Total revenue	642	1,798	1,781	2,228
Ancillary | Other
Disaggregation of Revenue [Line Items]
Total revenue	845	847	1,901	2,693
Small Business
Disaggregation of Revenue [Line Items]
Total revenue	2,190	1,723	7,703	6,975
Commission Bonus and Other
Disaggregation of Revenue [Line Items]
Total revenue	922	1,354	1,532	5,065
Commission
Disaggregation of Revenue [Line Items]
Total revenue	59,191	73,544	276,066	253,986
Other
Disaggregation of Revenue [Line Items]
Total revenue	4,723	20,740	18,619	35,472
Other | Sponsorship and Advertising Revenue
Disaggregation of Revenue [Line Items]
Total revenue	4,165	18,855	16,002	32,114
Other | Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 558	$ 1,885	$ 2,617	$ 3,358

Revenue - Commission Revenue by

Revenue - Commission Revenue by Segment (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Total revenue	$ 63,914	$ 94,284	$ 294,685	$ 289,458
Basic (in dollars per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)
Diluted (in dollars per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)
Commission
Disaggregation of Revenue [Line Items]
Total revenue	$ 59,191	$ 73,544	$ 276,066	$ 253,986
Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	47,590	56,052	252,469	219,500
Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue	1,744	1,122	6,154	5,005
Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 9,857	$ 16,370	$ 17,443	$ 29,481
Basic (in dollars per share)	$ 0.37	$ 0.62	$ 0.65	$ 1.14
Diluted (in dollars per share)	$ 0.37	$ 0.62	$ 0.65	$ 1.14
Change in revenue	$ (3,200)	$ (3,700)	$ (22,600)	$ (5,300)
Medicare | Commission
Disaggregation of Revenue [Line Items]
Total revenue	42,527	51,342	224,274	214,296
Medicare | Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	42,698	52,040	235,974	205,330
Medicare | Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue			0	0
Medicare | Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	(171)	(698)	(11,700)	8,966
Individual, Family and Small Business | Commission
Disaggregation of Revenue [Line Items]
Total revenue	16,664	22,202	51,792	39,690
Individual, Family and Small Business | Commission Revenue from Members Approved During the Period
Disaggregation of Revenue [Line Items]
Total revenue	4,892	4,012	16,495	14,170
Individual, Family and Small Business | Commission Revenue from Renewals of Small Business Members During the Period
Disaggregation of Revenue [Line Items]
Total revenue	1,744	1,122	6,154	5,005
Individual, Family and Small Business | Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 10,028	$ 17,068	$ 29,143	$ 20,515

Supplemental Financial Statem_3

Supplemental Financial Statement Information- Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020		Sep. 30, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Cash	$ 37,765	$ 39,552
Cash equivalents	119,765	4,207
Cash and cash equivalents	157,530	43,759	[1]
Restricted cash	3,354	3,354	[1]
Total cash, cash equivalents and restricted cash	$ 160,884	$ 47,113		$ 91,187	$ 26,820
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Supplemental Financial Statem_4

Supplemental Financial Statement Information - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	[1]
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 3,354,000		$ 3,354,000		$ 3,354,000
Write-off	0	$ 0	0	$ 0
China
Cash and Cash Equivalents [Line Items]
Deposits	$ 3,800,000		$ 3,800,000
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Supplemental Financial Statem_5

Supplemental Financial Statement Information - Schedule of Allowance for Credit Loss (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 2,026
Change in allowance	(207)
Ending balance	$ 1,819

Supplemental Financial Statem_6

Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance			$ 792,405	$ 589,222
Total revenue	$ 63,914	$ 94,284	294,685	289,458
Cash receipts			(311,310)	(237,213)
Net change in credit loss allowance			207	(1,650)
Ending balance	757,368	604,345	757,368	604,345
Medicare
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance			739,637	550,922
Cash receipts			(276,825)	(201,256)
Net change in credit loss allowance			188	(1,536)
Ending balance	687,274	562,426	687,274	562,426
Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance			52,768	38,300
Cash receipts			(34,485)	(35,957)
Net change in credit loss allowance			19	(114)
Ending balance	70,094	41,919	70,094	41,919
Commission Revenue from Members Approved During the Period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	47,590	56,052	252,469	219,500
Commission Revenue from Members Approved During the Period | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	42,698	52,040	235,974	205,330
Commission Revenue from Members Approved During the Period | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	4,892	4,012	16,495	14,170
Commission Revenue from Renewals of Small Business Members During the Period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	1,744	1,122	6,154	5,005
Commission Revenue from Renewals of Small Business Members During the Period | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue			0	0
Commission Revenue from Renewals of Small Business Members During the Period | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	1,744	1,122	6,154	5,005
Net Commission Revenue from Members Approved in Prior Periods
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	9,857	16,370	17,443	29,481
Net Commission Revenue from Members Approved in Prior Periods | Medicare
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	(171)	(698)	(11,700)	8,966
Net Commission Revenue from Members Approved in Prior Periods | Individual, Family and Small Business
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	$ 10,028	$ 17,068	$ 29,143	$ 20,515

Supplemental Financial Statem_7

Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Humana
Concentration Risk [Line Items]
Major customer revenue, percentage	27.00%	21.00%
UnitedHealthcare
Concentration Risk [Line Items]
Major customer revenue, percentage	24.00%	21.00%
Aetna
Concentration Risk [Line Items]
Major customer revenue, percentage	17.00%	20.00%
Centene
Concentration Risk [Line Items]
Major customer revenue, percentage	8.00%	11.00%

Supplemental Financial Statem_8

Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]
Prepaid maintenance contracts	$ 8,448	$ 7,715
Prepaid licenses	3,302	0
Prepaid expenses	23,828	6,628
Prepaid insurance	672	1,672
Others	403	646
Prepaid expenses and other current assets	$ 36,653	$ 16,661	[1]
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Short-term marketable securities	$ 70,212	$ 49,620	[1]
Level 1 | Recurring
Assets
Total assets measured at fair value	19,371	4,207
Level 2 | Recurring
Assets
Total assets measured at fair value	170,606	49,620
Level 3 | Recurring
Assets
Total assets measured at fair value	0	0
Carrying Value | Recurring
Assets
Total assets measured at fair value	189,977	53,827
Fair Value | Recurring
Assets
Total assets measured at fair value	189,977	53,827
Agency bonds
Assets
Short-term marketable securities	1,276
Agency bonds | Level 1 | Recurring
Assets
Short-term marketable securities	0	0
Agency bonds | Level 2 | Recurring
Assets
Short-term marketable securities	1,276	35,423
Agency bonds | Level 3 | Recurring
Assets
Short-term marketable securities	0	0
Agency bonds | Carrying Value | Recurring
Assets
Short-term marketable securities	1,276	35,423
Agency bonds | Fair Value | Recurring
Assets
Short-term marketable securities	1,276	35,423
Commercial paper
Assets
Short-term marketable securities	66,414
Commercial paper | Level 1 | Recurring
Assets
Short-term marketable securities	0	0
Commercial paper | Level 2 | Recurring
Assets
Short-term marketable securities	66,414	14,197
Commercial paper | Level 3 | Recurring
Assets
Short-term marketable securities	0	0
Commercial paper | Carrying Value | Recurring
Assets
Short-term marketable securities	66,414	14,197
Commercial paper | Fair Value | Recurring
Assets
Short-term marketable securities	66,414	14,197
Corporate bond
Assets
Short-term marketable securities	2,522
Corporate bond | Level 1 | Recurring
Assets
Short-term marketable securities	0
Corporate bond | Level 2 | Recurring
Assets
Short-term marketable securities	2,522
Corporate bond | Level 3 | Recurring
Assets
Short-term marketable securities	0
Corporate bond | Carrying Value | Recurring
Assets
Short-term marketable securities	2,522
Corporate bond | Fair Value | Recurring
Assets
Short-term marketable securities	2,522
Money market funds
Assets
Cash equivalents	19,371
Money market funds | Level 1 | Recurring
Assets
Cash equivalents	19,371	4,207
Money market funds | Level 2 | Recurring
Assets
Cash equivalents	0	0
Money market funds | Level 3 | Recurring
Assets
Cash equivalents	0	0
Money market funds | Carrying Value | Recurring
Assets
Cash equivalents	19,371	4,207
Money market funds | Fair Value | Recurring
Assets
Cash equivalents	19,371	$ 4,207
Commercial paper
Assets
Cash equivalents	100,394
Commercial paper | Level 1 | Recurring
Assets
Cash equivalents	0
Commercial paper | Level 2 | Recurring
Assets
Cash equivalents	100,394
Commercial paper | Level 3 | Recurring
Assets
Cash equivalents	0
Commercial paper | Carrying Value | Recurring
Assets
Cash equivalents	100,394
Commercial paper | Fair Value | Recurring
Assets
Cash equivalents	$ 100,394
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Fair Value Measurements - Contr

Fair Value Measurements - Contractual Maturities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Amortized Cost
Due in 1 year	$ 189,980
Fair Value
Due in 1 year	$ 189,977

Fair Value Measurements - Unrea

Fair Value Measurements - Unrealized Gains and Losses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	[1]
Cash equivalents
Cash and cash equivalents	$ 157,530	$ 43,759
Short-term marketable securities
Fair Value	70,212	$ 49,620
Total	189,980
Unrealized Gain	4
Unrealized Loss	(7)
Fair Value	189,977
Money market funds
Cash equivalents
Cash and cash equivalents	19,371
Unrealized Gain	0
Unrealized Loss	0
Fair Value	19,371
Commercial paper
Cash equivalents
Cash and cash equivalents	100,398
Unrealized Gain	0
Unrealized Loss	(4)
Fair Value	100,394
Agency bonds
Short-term marketable securities
Amortized Cost	1,276
Unrealized Gain	0
Unrealized Loss	0
Fair Value	1,276
Commercial paper
Short-term marketable securities
Amortized Cost	66,413
Unrealized Gain	4
Unrealized Loss	(3)
Fair Value	66,414
Corporate bond
Short-term marketable securities
Amortized Cost	2,522
Unrealized Gain	0
Unrealized Loss	0
Fair Value	$ 2,522
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details)	Sep. 30, 2021security
Fair Value Disclosures [Abstract]
Number of securities in net loss positions	41

Equity - Narrative (Details)

Equity - Narrative (Details) - shares	1 Months Ended	3 Months Ended	9 Months Ended
	Nov. 08, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 22, 2021	Dec. 31, 2020
Equity, Class of Treasury Stock [Line Items]
Shares reserved for future issuance (in shares)				410,000
Granted (in shares)			0
Number of shares repurchased under share repurchase plan (in shares)		0	0
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)			1,300,000
Treasury stock (in shares)		12,000,000	12,000,000		11,800,000
Subsequent Event
Equity, Class of Treasury Stock [Line Items]
Granted (in shares)	390,584
Previous share repurchase programs
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased under share repurchase plan (in shares)			10,700,000

Equity - Schedule of Stock-Base

Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5,234	$ 6,332	$ 24,881	$ 21,722
Amount capitalized in internal-use software	772	548	1,875	1,278
Total stock-based compensation	6,006	6,880	26,756	23,000
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	4,666	6,078	23,031	20,855
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	82	254	402	867
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	486	0	1,448	0
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,297	1,869	6,922	5,138
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	740	527	1,901	1,762
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	2,380	1,430	7,483	2,965
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	(183)	$ 2,506	8,575	$ 11,857
General and administrative | Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ (4,100)		$ (4,100)

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) $ / shares in Units, $ in Thousands	Apr. 30, 2024day	Jun. 30, 2023	Apr. 30, 2021USD ($)state$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Apr. 30, 2027day	Aug. 17, 2023	May 31, 2021$ / shares	Feb. 17, 2021USD ($)	Dec. 31, 2020USD ($)	[1]
Temporary Equity [Line Items]
Sale of stock, shares issued (in shares) | shares			2,250,000
Preferred Stock, par value (in dollars per share) | $ / shares			$ 0.001
Gross proceeds			$ 225,000
Carrying amount			214,025	$ 225,438					$ 0
Issuance costs			$ 10,975
Dividend rate				8.00%
Stated value (in dollars per share) | $ / shares				$ 100
Conversion rate (in dollars per share) | $ / shares							$ 79.5861
Redemption put right, percentage of accrued value				135.00%
Number of votes per share | state			1
Asset coverage ratio								200.00%
Shares converted (in shares) | shares				0
Accrued paid-in-kind dividends, common stock equivalent, as-converted (in shares) | shares				2,900,000
H.I.G
Temporary Equity [Line Items]
Number of nominations to board of directors | state			1
Minimum common stock ownership percentage needed to nominate individual to board of directors			30.00%
Minimum ownership percentage needed for consent to incur debt in excess of $175 million								30.00%
Minimum
Temporary Equity [Line Items]
Minimum liquidity amount								$ 65,000
Maximum
Temporary Equity [Line Items]
Minimum liquidity amount								$ 125,000
Scenario, Forecast
Temporary Equity [Line Items]
Dividend rate, payable-in-kind		6.00%
Dividend rate, cash		2.00%
Redemption put right, percentage of accrued value					135.00%
Redemption call right, number of days for written notice | day					30
Threshold percentage of conversion price	167.50%
Threshold consecutive trading days | day	20
Threshold trading days | day	30
Asset coverage ratio						250.00%
[1]	See Note 1 – Summary of Business and Significant Accounting Policies

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary of Stock (Details) - USD ($) $ in Thousands	Apr. 30, 2021	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Gross proceeds	$ 225,000
Less: issuance costs	10,975
Net proceeds	214,025
Increase (Decrease) in Temporary Equity [Roll Forward]
Accrued paid-in-kind dividends		$ 7,643
Change in preferred stock redemption value		3,770
Balance as of September 30, 2021	$ 214,025	$ 225,438

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Numerator:
Net loss attributable to common stockholders	$ (59,948)	$ (14,505)	$ (83,636)	$ (14,423)
Denominator:
Shares used in per share calculation - basic (in shares)	26,786	26,487	26,688	25,838
Dilutive effect of common stock (in shares)	0	0	0	0
Shares used in diluted share calculation (in shares)	26,786	26,487	26,688	25,838
Net loss attributable to common stockholders per share - basic (in usd per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)
Net loss attributable to common stockholders per share - diluted (in usd per share)	$ (2.24)	$ (0.55)	$ (3.13)	$ (0.56)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	4,285	1,013	2,992	1,201
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,866	0	1,595	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	1,134	599	1,055	748
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	278	414	330	453
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	7	0	12	0

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Thousands	Jul. 01, 2019plaintiff	Apr. 30, 2020claim	Oct. 13, 2020claim	Sep. 30, 2021USD ($)
Loss Contingencies [Line Items]
Remainder of 2021				$ 2,845
2022				10,407
2023				8,067
2024				2,256
2025				0
Thereafter				0
Total				$ 23,575
New claims filed | claim		2	2
Le'Vias Compliant
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff	2

Segment and Geographic Inform_3

Segment and Geographic Information - Segment Operating Results (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment			2
Total revenue	$ 63,914	$ 94,284	$ 294,685	$ 289,458
Stock-based compensation expense	(5,234)	(6,332)	(24,881)	(21,722)
Depreciation and amortization	(4,899)	(2,995)	(12,840)	(7,911)
Amortization of intangible assets	(121)	(287)	(416)	(1,207)
Restructuring and reorganization charges	(573)	0	(3,004)	0
Other income (expense), net	189	(101)	511	724
Loss before benefit from income taxes	(65,848)	(20,948)	(91,501)	(25,346)
Amortization of internally developed software	3,400	2,100	9,140	5,307
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	63,914	94,284	294,685	289,458
Segment profit (loss)	(40,383)	4,348	(7,665)	48,146
Operating Segments | Medicare
Segment Reporting Information [Line Items]
Total revenue	46,381	70,361	240,633	246,891
Segment profit (loss)	(52,882)	(14,139)	(46,141)	23,993
Operating Segments | Individual, Family and Small Business
Segment Reporting Information [Line Items]
Total revenue	17,533	23,923	54,052	42,567
Segment profit (loss)	12,499	18,487	38,476	24,153
Corporate
Segment Reporting Information [Line Items]
Segment profit (loss)	$ (14,827)	$ (15,581)	$ (43,206)	$ (43,376)

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule Of Long-Lived Assets By Geographical Area (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Long-lived assets	$ 46,102	$ 41,065
United States
Segment Reporting Information [Line Items]
Long-lived assets	45,465	40,500
China
Segment Reporting Information [Line Items]
Long-lived assets	$ 637	$ 565

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
UnitedHealthcare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	21.00%	17.00%	21.00%	21.00%
Aetna
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	15.00%	12.00%	20.00%	14.00%
Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	20.00%	26.00%	18.00%	21.00%
Centene
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	11.00%	8.00%	12.00%	10.00%

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 1.9	$ 2.1	$ 5.7	$ 6.4
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	2 years		2 years
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	8 years		8 years

Leases - Supplemental Informati

Leases - Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term of operating leases	6 years 7 months 6 days		7 years 2 months 12 days
Weighted-average discount rate used to recognize operating lease right-of-use-assets	5.40%		5.40%
Operating lease expense	$ 5,738	$ 6,411
Cash outflows related to operating leases	$ 5,722	$ 5,173

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating leases
Remainder of 2021	$ 1,926
2022	7,701
2023	8,033
2024	7,832
2025	8,009
Thereafter	19,407
Total lease payments	52,908
Less imputed interest	(10,200)
Total	42,708
Sublease income, remainder of 2021	300
Sublease income, 2022	400
Sublease income, 2023	$ 400

Restructuring and Reorganizat_3

Restructuring and Reorganization - Restructuring and Other Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restructuring Reserve [Roll Forward]
Beginning balance			$ 0
Restructuring and reorganization charges	$ 573	$ 0	3,004	$ 0
Payments			(2,466)
Ending balance	$ 538		$ 538

Restructuring and Reorganizat_4

Restructuring and Reorganization - Narrative (Details) $ in Thousands	1 Months Ended	2 Months Ended	3 Months Ended		9 Months Ended
	Feb. 28, 2021employee	Mar. 31, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Restructuring Cost and Reserve [Line Items]
Positions eliminated | employee	89
Percentage of total workforce	5.00%
Pre-tax restructuring charges		$ 2,400
Accrued restructuring charges			$ 538		$ 538			$ 0
Credit to stock-based compensation expense			5,234	$ 6,332	24,881	$ 21,722
General and administrative
Restructuring Cost and Reserve [Line Items]
Credit to stock-based compensation expense			(183)	$ 2,506	8,575	$ 11,857
Chief Executive Officer | General and administrative
Restructuring Cost and Reserve [Line Items]
Credit to stock-based compensation expense			$ (4,100)		$ (4,100)
Scenario, Forecast
Restructuring Cost and Reserve [Line Items]
Expected cost							$ 1,900

Debt (Details)

Debt (Details) - USD ($)	Dec. 20, 2019	Sep. 17, 2018	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Borrowings under line of credit			$ 0
Credit Agreement Amendment
Debt Instrument [Line Items]
Debt issuance costs					$ 500,000
Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity	$ 75,000,000	$ 40,000,000
Commitment fee percentage		0.50%
Facility fee percentage	0.50%	1.75%
Maximum borrowing capacity	$ 75,000,000	$ 40,000,000
Covenant, minimum cash and cash equivalents	6,000,000	6,000,000
Covenant, maximum cash and cash equivalents	11,300,000
Minimum liquidity	10,000,000
Maximum liquidity	$ 18,800,000
Debt issuance costs		1,200,000
Revolving Credit Facility | Credit Agreement Amendment
Debt Instrument [Line Items]
Debt issuance costs			$ 500,000	$ 700,000
Letter of Credit
Debt Instrument [Line Items]
Borrowing capacity		$ 5,000,000
Eligible Commissions Receivables, Preceding Three Months | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage			80.00%
Eligible Commissions Receivables, Succeeding Three Months | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage			80.00%
Eligible Commissions Receivables, Succeeding Six Months | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing base percentage			50.00%

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Loss before benefit from income taxes	$ (65,848)	$ (20,948)	$ (91,501)	$ (25,346)
Benefit from income taxes	$ (12,834)	$ (6,443)	$ (19,278)	$ (10,923)
Effective tax rate	19.50%	30.80%	21.10%	43.10%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ 12,834	$ 6,443	$ 19,278	$ 10,923
Effective tax rate	19.50%	30.80%	21.10%	43.10%

Uncategorized Items - ehth-2021

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-13 [Member]